In a significant move to combat obesity in India, Novo Nordisk India and Emcure Pharma have teamed up to launch Poviztra, a semaglutide injection branded after Wegovy, which debuted in the nation in June 2025. This initiative targets chronic weight management and reducing cardiovascular risks associated with obesity.

This strategic alliance will improve the availability and marketing effectiveness of semaglutide, specifically through pharmacies, extending its reach beyond areas previously covered by Novo Nordisk India. Obesity stands as a chronic condition impacting millions, creating an urgent demand for efficacious medical solutions.

Emcure Pharma will leverage its extensive geographical knowledge and marketing prowess to distribute Poviztra efficiently. The partnership is a step towar

See Full Page